TON - May 2018, Vol 11, No 2

The Oncology Nurse-APN/PA spoke with Salimah H. Meghani, PhD, MBE, RN, FAAN, a faculty member at the University of Pennsylvania School of Nursing, Philadelphia, about her various roles and thoughts on what is exciting in the field of palliative care.

The Academy of Oncology Nurse & Patient Navigators had a strong presence at the first of the Biden Cancer Initiative’s “Conversation with Dr Biden,” on March 10, 2018. These conversations provide members of the patient support network with the opportunity to share their perspectives on the cancer journey.

Based on research presented at the 2018 National Comprehensive Cancer Network Annual Conference, patients weighing 60 kg to 85 kg who often receive lower-than-recommended doses of filgrastim, without evidence of its noninferiority to recommended doses, is found to be not only acceptable, but also cost-saving.

The May issue of The Oncology Nurse-APN/PA (TON) is full of important news and updates for oncology nurses.

Interim data from a recent clinical trial of nelipepimut-S plus trastuzumab showed a disease-free survival advantage compared with trastuzumab alone in patients with HER2 1+/2+ breast cancer.

In 2 independent studies presented at the 2018 American Association for Cancer Research Annual Meeting, chlamydia trachomatis infection was shown to increase the risk for developing ovarian cancer by approximately 2-fold.

“The combination of atezolizumab and cobimetinib represents the first potential immune-modifying combination for patients with microsatellite stable metastatic colorectal cancer,” said Johanna C. Bendell, MD, at the 2018 Gastrointestinal Cancers Symposium.

Paige Johnson, DNP, CPNP, CPHON, discusses some of the characteristics that contribute to poor prognosis in infants with acute lymphoblastic leukemia, the results of clinical trials evaluating newer therapies to treat the disease, and what the future holds in terms of novel strategies.

At the 2018 Genitourinary Cancers Symposium, lead investigator Alison Jane Birtle, MD, MBBS, MRCP, FRCR, presented the results of the phase 3 POUT clinical trial, which showed that adjuvant chemotherapy had impressive gains in the disease-free survival and metastasis-free survival in upper-tract urothelial cancer

Page 1 of 2
Results 1 - 10 of 13